A systematic review published in the Cochrane Database of Systematic Reviews has concluded that drugs targeting amyloid proteins in Alzheimer's patients do not yield clinically meaningful benefits. The analysis, conducted by researchers from the IRCCS Institute of Neurological Sciences of Bologna, Italy, evaluated data from 17 clinical trials involving over 20,300 participants with mild cognitive impairment or mild dementia. While these drugs can effectively remove amyloid beta proteins from the brain, the study found no significant impact on cognitive decline or dementia severity. Lead author Francesco Nonino, a neurologist, stated that despite statistically significant results in early trials, they do not translate into meaningful clinical improvements for patients. Furthermore, the review highlighted that these drugs increase the risk of brain swelling and bleeding, observed in scans without apparent symptoms. Senior author Edo Richard from Radboud University Medical Centre in the Netherlands emphasized the need for research to focus on alternative treatment pathways, given the lack of correlation between amyloid removal and clinical benefit.